|
| |
Cyclacel Pharmaceuticals to host conference call on upcoming
Sapacitabine Phase II trials
-- Company Management to Provide Details of Sapacitabine
Phase II Trial Plans --
BERKELEY HEIGHTS, NJ, December 12, 2007 – Cyclacel Pharmaceuticals, Inc.
(NASDAQ: CYCC, NASDAQ: CYCCP) announced today that it will host a conference
call featuring Dr. Hagop Kantarjian, M.D. to provide an update of sapacitabine
Phase II clinical plans in patients with elderly AML, review Phase I
sapacitabine data reported at the meeting of the American Society of Hematology
(ASH) on December 8, and comment on the current therapeutic landscape in acute
myeloid leukemia (AML). The call will occur on Wednesday, December 19, 2007 at
9:30 AM Eastern Time.
Dr. Kantarjian will comment on current patient needs in the treatment of AML/MDS
and on the significance of sapacitabine data presented at ASH in this context.
Dr. Kantarjian is professor of medicine and chairman of the leukemia department
at The University of Texas M.D. Anderson Cancer Center and was the primary
investigator in Cyclacel’s Phase I sapacitabine clinical study. Additionally,
Dr. Judy Chiao, Cyclacel’s Vice President of Clinical Development and Regulatory
Affairs, will provide details of the Company’s previously announced Phase II
trial of sapacitabine in elderly AML, including patient eligibility criteria and
trial endpoints.
Conference call and webcast information: 9:30 AM ET , Wednesday, December 19
2007:
• U.S./Canada call: +1 (877) 493-9121, conference ID: 28030310.
• International call: +1 (973) 582-2750, conference ID: 28030310.
• Webcast: http://w.on24.com/r.htm?e=99426&s=1&k=EA59D227D2A8068D191C9194D3247CA1
or via Cyclacel Pharmaceuticals’ website at www.cyclacel.com.
• The webcast will be archived for 90 days and the audio replay will be archived
for seven days.
• Access numbers for the audio replay are U.S./Canada: (800) 642-1687;
International: (706) 645-9291; conference ID: 28030310.
-ENDS-
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a biopharmaceutical company dedicated to the discovery, development
and commercialization of novel, mechanism-targeted drugs to treat human cancers
and other serious disorders. Cyclacel’s ALIGN Pharmaceuticals subsidiary markets
directly in the U.S. Xclair® Cream for radiation dermatitis, Numoisyn® Liquid
and Numoisyn® Lozenges for xerostomia. Three Cyclacel drugs are in clinical
development. Sapacitabine (CYC682), an orally-available, cell cycle modulating
nucleoside analog, is in Phase II for the treatment of cutaneous T-cell lymphoma
(CTCL) and in Phase I in patients with hematologic malignancies. Seliciclib
(CYC202), an orally-available CDK (cyclin dependent kinase) inhibitor, is in two
randomized Phase II studies for the treatment of lung cancer and nasopharyngeal
cancer. CYC116, an orally-available, Aurora kinase and VEGFR2 inhibitor, is in
Phase I development in patients with solid tumors. Several additional programs
are at an earlier stage. Cyclacel’s strategy is to build a diversified
biopharmaceutical business focused in oncology, hematology and other therapeutic
areas based on a portfolio of commercial products and a development pipeline of
novel drug candidates.
Please visit
http://www.cyclacel.com/cyc/investors/news/pressreleases for additional
information.
Note: The Cyclacel logo and Cyclacel® are trademarks of Cyclacel
Pharmaceuticals, Inc. Numoisyn® and Xclair® are trademarks of Sinclair Pharma
plc.
Forward-Looking Statements & Risk Factors
This news release contains certain forward-looking statements that involve risks
and uncertainties that could cause actual results to be materially different
from historical results or from any future results expressed or implied by such
forward-looking statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety, and intended utilization of
Cyclacel's product candidates, the conduct and results of future clinical
trials, plans regarding regulatory filings, future research and clinical trials
and plans regarding partnering activities. Factors that may cause actual results
to differ materially include the risk that product candidates that appeared
promising in early research and clinical trials do not demonstrate safety and/or
efficacy in larger-scale or later clinical trials, the risk that Cyclacel will
not obtain approval to market its products, the risks associated with reliance
on outside financing to meet capital requirements, and the risks associated with
reliance on collaborative partners for further clinical trials, development and
commercialization of product candidates. You are urged to consider statements
that include the words "may," "will," "would," "could," "should," "believes,"
"estimates," "projects," "potential," "expects," "plans," "anticipates,"
"intends," "continues," "forecast," "designed," "goal," or the negative of those
words or other comparable words to be uncertain and forward-looking. These
factors and others are more fully discussed under "Risk Factors" in the Annual
Report on Form 10-K for the year ended December 31, 2006, as supplemented by the
interim quarterly reports, filed with the SEC.
European media and investor relations:
College Hill Life Sciences
Sue Charles / Justine Lamond
Ph: +44 (0)20 7866 7857
Cyclacel@collegehill.com
| |
|
